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Summary Purpose Continuous treatment with FOLFOX
therapy is associated with peripheral nerve toxicity, and to
improve this inconvenient side effect various methods of ad-
ministration are being investigated. A regimen of intermittent
oxaliplatin administration by continuous infusion therapy, i.e.,
modified FOLFOX7 (mFOLFOX7) + bevacizumab, was
designed with the goal of alleviating severe peripheral nerve
disorders and hematological toxicity. A phase II clinical study
was conducted to evaluate the efficacy and safety of this
regimen.Methods Previously untreated patients were assigned
to mFOLFOX7 (oxaliplatin 85 mg/m2, levofolinate [l-LV]
200 mg/m2, 5-fluorouracil [5-FU] 2400 mg/m2) +
bevacizumab (5 mg/kg) administered every 2 weeks for 8 cy-
cles, maintenance without oxaliplatin for 8 cycles, and
reintroduction of mFOLFOX7 + bevacizumab for 8 cycles or
until disease progression. Progression free survival (PFS) fol-
lowing the first dose (PFS 1) and following reintroduction of
oxaliplatin (PFS 2) were used as indices for assessing the
efficacy of intermittent administration. Results Fifty-two pa-
tients were enrolled, with median age of 64 years (range, 36–
74). Median PFS 1 was 11.8 months (95 % confidence interval
[CI], 9.5 to 13.7), median time to treatment failure was
10.3 months (95 % CI, 5.6 to 12.1), percentage of patients with
neutropenia of grade 3 or higher was 7.8 %, and percentage
with peripheral nerve disorders was 3.9 %. Response rate was
50 %, and 84.4 % of patients who started modified simplified
LV5FU2 + bevacizumab were reintroduced to oxaliplatin.
Conclusion By excluding 5-FU bolus administration and ad-
ministering bevacizumab continuously the mFOLFOX7 +
bevacizumab regimen with preplanned withdrawal of
oxaliplatin showed high tolerability and prevented severe pe-
ripheral neuropathy and neutropenia without reducing efficacy.
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Introduction
In the 1980s, 5-fluorouracil (5-FU)/leucovorin (LV) was the
standard recommended first-line therapy for unresectable
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metastatic colorectal cancer (mCRC) [1, 2]. Since then,
irinotecan and oxaliplatin have been developed, and 5-
FU/LV/oxaliplatin (FOLFOX) [3–5] and 5-FU/LV/irinotecan
(FOLFIRI) [6] are now recommended in the NCCN
Guidelines in addition to 5-FU/LV therapy. Hurwitz et al.
reported prolonged survival by combining bevacizumab with
irinotecan plus bolus 5-FU (IFL) [7], and combinations of
chemotherapy with several molecular targeting agents are
now currently recommended in the NCCN Guidelines and in
the guidelines from other countries. Prolonged survival as an
additive effect of molecular targeting agents has been reported
in first-line therapy with 5-FU/LV plus bevacizumab [8], and
the additive effect of bevacizumab to an oxaliplatin-based
regimen was demonstrated in the NO16966 study [9].
As described above, 5-FU/LV plus bevacizumab and
FOLFOX plus bevacizumab have become established as
standard, first-line therapies for unresectable mCRC.
However, peripheral neuropathy and serious hematological
toxicity, which are cumulative toxicities of oxaliplatin in
FOLFOX, have been obstacles to continuous therapy [10].
To address this issue, oxaliplatin withdrawal (the stop-and-
go concept) was systematically incorporated into the
OPTIMOX1 study [11] and the OPTIMOX2 study [12]
and was shown to be useful. Subsequently, a randomized
phase III clinical study of bevacizumab combined with
FOLFOX (the CONcePT trial) was conducted in order to
validate the stop-and-go concept and to examine the incidence
of peripheral neuropathy depending on the administration of
calcium gluconate and magnesium sulfate (Ca/Mg formula-
tion), with results reported at the American Society of Clinical
Oncology Annual Meeting in 2008 [13]. In that study, contin-
uous administration of oxaliplatin (continuous oxaliplatin; CO)
and intermittent administration of oxaliplatin (intermittent
oxaliplatin; IO) were compared using modified FOLFOX7
(mFOLFOX7; oxaliplatin 85 mg/m2) plus bevacizumab.
Median time to treatment failure (TTF), the primary endpoint,
was 4.2 months in the CO arm and 5.6 months in the IO arm
(HR, 0.58; P=0.0025), demonstrating that the IO arm was
significantly better. The incidence of peripheral neuropathy
of grade 3 or higher, the rate of discontinuation of therapy
due to peripheral neuropathy, and the need to delay the treat-
ment and/or reduce dose were all lower in the IO arm. That
report suggested the oxaliplatin stop-and-go concept to be
favorable even when bevacizumab was combined with
FOLFOX, but it has not been established as the standard of
care, and the clinical question of reintroducing oxaliplatin
remains.
Therefore, we conducted the phase II CRAFT (Confirmation
of Avastin and intermittent mFOLFOX7 Therapy in advanced
colorectal cancer) study in order to examine the efficacy and
safety of a regimen of mFOLFOX7 plus bevacizumab with
intermittent oxaliplatin administration for Japanese colorectal
cancer patients.
Materials and methods
This study was a multicenter phase II clinical study to
examine the efficacy and safety of intermittent oxaliplatin
administration in mFOLFOX7 plus bevacizumab as the
first-line therapy for patients with unresectable colorectal
cancer. The primary endpoint was progression-free survival
1 (PFS 1, the period from the start of the treatment to the
point of first progression); secondary endpoints were time to
treatment failure (TTF), response rate 1 (RR 1, the response
rate during the first oxaliplatin treatment), progression-free
survival 2 (PFS 2, the period from the first progression
during maintenance to the second progression after
reintroduction of oxaliplatin), response rate 2 (RR 2, the
response rate during reintroduction of oxaliplatin following
the first progression), and the safety.
Patient eligibility
Patients were entered into the study if they fulfilled the
following inclusion criteria: 1) colorectal cancer was defi-
nitely diagnosed histologically; 2) the colorectal cancer was
unresectable and metastatic; 3) the disease had not been
treated with chemotherapy or radiation therapy; 4) at least
one lesion was evaluable; 5) age 20 to 79 years; 6) the
Eastern Cooperative Oncology Group (ECOG)
Performance Status (PS) was 0 or 1; and 7) they had suffi-
cient bone-marrow, liver, and kidney functions. Patients
were excluded if there was 1) suspicion of brain metastasis;
2) suspicion of arterial thromboembolism; 3) chronic in-
flammatory disease such as rheumatoid arthritis; 4) bleeding
tendencies; 5) uncontrollable peptic ulcer, hypertension,
diarrhea, or infection; 6) heart disease with symptoms; or
7) pregnancy or lactation.
This study was conducted in accordance with the World
Medical Association Declaration of Helsinki and the Ethical
Guidelines for Clinical Studies. The scientific and ethical
validity of this study was reviewed by the Ethical Review
Board of each participating facility, and the study was
conducted after receiving their approval. Informed consent
was obtained from all enrolled patients in writing before
enrollment. This study was registered with UMIN-CTR
(number: UMIN000002354).
Treatment plan and evaluation
The protocol treatment was started within 14 days after
enrollment of patients who were determined to be eligible.
On day 1, bevacizumab 5 mg/kg was administered by initial
90-min intravenous infusion (which could be shortened to
60 min at the second time and to 30 min from the third
time), then oxaliplatin 85 mg/m2 and levofolinate (l-LV)
200 mg/m2 were administered by 120-min intravenous
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infusion, 5-FU 2400 mg/m2 was administered by 46-h (days
1–2) continuous intravenous infusion, with 12 days of drug
withdrawal thereafter. These 14 days constituted 1 cycle,
and cycles 1–8 were conducted (block A). Thereafter, 8 cy-
cles (cycles 9–16) were conducted without oxaliplatin
(block B). Then oxaliplatin was reintroduced for 8 cycles
(block C), so that a total of 24 cycles was administered as
the protocol treatment (Fig. 1). Protocol treatment was con-
tinued as long as it did not conflict with the criteria for
discontinuing treatment. However, the following cases were
defined as the end of protocol treatment:
(1) The 24 cycles (block A followed by block B and then
block C) prescribed in the protocol had been complet-
ed. However, if progressive disease (PD) was con-
firmed before the completion of 8 cycles in block B,
the end of protocol was defined as the end of block C
following reintroduction of oxaliplatin.
(2) The patient became operable as a result of the efficacy
of treatment (with the day of surgery defined as the end
of protocol treatment).
Computerized tomography (CT)/magnetic resonance im-
aging (MRI) was performed every 8 weeks during the
protocol treatment, counting from the day of enrollment, in
order to measure and evaluate target lesions, evaluate non-
target lesions, and check for the appearance of new lesions.
Image assessment by CT/MRI or other method was also
permitted as necessary. If the tumor site was measured by
a method other than CT/MRI, the tumor was evaluated
before treatment and the same method was continued until
PD. As a rule, CT/MRI was also conducted using the same
measurement method and the same slice thickness as used in
examination at baseline. Evaluation of tumor reduction was
according to Response Evaluation Criteria in Solid Tumors
(RECIST, version 1.1).
Adverse events were evaluated by the National Cancer
Institute Common Terminology Criteria for Adverse Events
(NCI-CTCAE v3.0) in all enrolled patients who received the
protocol treatment at least once. The frequency and grade of
the most serious clinical findings and laboratory test values
in each cycle were tabulated. Patients were observed care-
fully for previously reported typical adverse drug reactions
to bevacizumab and oxaliplatin, including hemorrhage,
Fig. 1 Chemotherapy regimens
Fig. 2 Definition of progression free survival. PFS 2: first PD desig-
nated as starting point
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thrombosis, gastrointestinal perforation, increased blood
pressure, hemotoxicity, and peripheral neuropathy.
Definition of endpoints
In this study, the following definitions were used to assess
therapeutic effect: PFS 1 (Fig. 2) is the period from the day
of enrollment to the confirmation of PD or death from any
cause, whichever comes first; TTF is the period from the
day of enrollment until the date of discontinuation of treat-
ment, the date of PD confirmation, or the date of death,
whichever comes first; RR 1 is the percentage of patients
whose best overall response is either CR or PR; PFS 2
(Fig. 2) is the period from the date of first PD during
modified simplified LV5FU2 (msLV5FU2) plus
bevacizumab to the date of confirmation of PD (second
PD after the day of enrollment) after reintroduction of
mFOLFOX7 plus bevacizumab, or the date of death from
any cause is confirmed, whichever comes first; RR 2 is the
response rate during reintroduction of oxaliplatin following
the first PD.
Statistical determination of target sample size
In the NO16966 study [9], a phase III clinical study of
FOLFOX4 or capecitabine/oxaliplatin (XELOX)
with/without bevacizumab, the median PFS by on-
treatment analysis excluding PD cases from at least 29 days
after the final administration of the study drug was
10.4 months. In the PACCE trial [14], a phase III clinical
study conducted to confirm the additive effect of
panitumumab to FOLFOX plus bevacizumab, the median
PFS for FOLFOX plus bevacizumab was 11.2 months.
Therefore, the threshold PFS in this study was assumed to
be 7 months considering PFS in the phase III study of
FOLFOX4 [15], and the anticipated PFS was set at
10.5 months. Level of significance was 0.05, power was
80 %, and the required number of cases determined by using
the Southwest Oncology Group’s one-arm survival design
(http://www.swogstat.org/statoolsout.html) was 42 patients.
The target number of cases in this study was 50 patients,
considering a dropout rate of 10 %.
Analysis plan
PFS and TTF survival curves were estimated by the Kaplan–
Meier method, median survival time was calculated, and the
two-sided 95 % confidence interval was calculated.
As for the response rate, antitumor effect (overall effect)
was compiled for patients with measurable lesions among the
per protocol set (PPS). Exact confidence interval based on
binomial distribution was used for the interval estimation.
Results
Patient characteristics
Fifty-two patients from 18 institutions were enrolled from
February 2009 to June 2010. Four out of the 52 patients were
excluded as subjects of the efficacy analysis due to ineligibil-
ity after enrollment; therefore, the efficacy analysis was
conducted with 48 patients. The safety analysis set included
51 patients, all enrolled patients who received the protocol
treatment at least once. Data cutoff was May 2011, and the
median observation period was 9.3 months. Baseline patient
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characteristics are shown in Table 1. Median age was 64 years
(36–74), male/female ratio was 32/20, colon cancer/rectal
cancer ratio was 25/27, and ECOG PS 0/1 ratio was 43/9.
Treatment status
The study profile of protocol treatment is shown in Fig. 3.
Of the 52 patients enrolled, 48 started the protocol treat-
ment. The completion rate of block A treatment was 70.8 %
(34/48). The breakdown of the 14 patients who discontinued
treatment during block Awas adverse events in 7 cases, PD
in 4 cases, withdrawal of consent in 1 case, and other
reasons in 2 cases. In addition, 1 patient deviated from
protocol by continuing the treatment, and 1 patient
discontinued due to hepatectomy after completing block A.
The rate of completion of block B treatment was 78.1 %
(25/32). The breakdown of the seven patients who
discontinued treatment during block B was PD in four cases,
adverse event in one case, withdrawal of consent in one
case, and hepatectomy in one case. A total of six patients
with confirmed PD—three who discontinued block B and
three who completed block B—were moved to block C as
stipulated in the protocol. In addition, one patient
discontinued due to withdrawal of consent after completing
block B.
The rate of completion of block C treatment was 59.3 %
(16/27). The breakdown of the 11 patients who discontinued
treatment during block C was PD in eight cases, adverse
events in two cases, and withdrawal of consent in one case.
The protocol completion rate was 33.3 % (16/48), and
median TTF was 10.3 months (95 % confidence interval
[CI], 5.6 to 12.1) (Fig. 4a).
The percentage of patients reintroduced to oxaliplatin at
movement from block B to block C was 84.4 % (27/32).
Fig. 3 Study profile
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Relative dose intensity in each treatment block was
≥89 % for 5-FU and l-LV, ≥86 % for bevacizumab, and
≥96 % for oxaliplatin (blocks A and C).
Efficacy
The median PFS 1, was 11.8 months (95 % CI, 9.5 to
13.7) (Fig. 4b). The secondary endpoint RR 1 was
50 % (23/46) in the 46 patients who were evaluable
by RECIST. The maximum rate of tumor reduction at
the time of best overall response during the protocol
treatment was −91 % (range, +126.0 to −91.0 %). There
were six patients to whom PFS 2 and RR 2 were
applicable after oxaliplatin reintroduction as patients
with first PD during or immediately after block B
treatment. The median PFS 2 and RR 2 were 4.2 months
(95 % CI, 2.8 to 23.5) and 0 % (0/6), with three cases
of stable disease (SD) and three cases of PD.
Exploratory analysis showed median survival time to
be 25.4 months (95 % CI, 18.5 to 35.2).
Fig. 4 a Kaplan-Meier
estimate of time to treatment
failure. b Kaplan-Meier
estimate of progression free
survival
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Safety
The main adverse drug reactions of grade 3 or higher in the
51 patients of the safety analysis set were neutropenia 7.8 %
(four patients), peripheral neuropathy 3.9 % (two patients),
hypertension 3.9 % (two patients), venous thromboembo-
lism 3.9 % (two patients), and allergic reaction 2.0 % (one
patient). Grade 4 adverse drug reactions were neutropenia,
decreased hemoglobin, and ileus, each 2.0 % (one patient
each). In addition, gastrointestinal perforation and clinically
significant hemorrhage or proteinuria of grade 3 or higher,
which are characteristic of bevacizumab, were not observed
(Table 2). Total allergic reactions observed were 9.8 % (5/51
patients), which led to discontinuation of protocol treatment
in three cases. Discontinuation of protocol due to peripheral
neuropathy occurred in one case.
Discussion
This trial is the first investigational study of the oxaliplatin
stop-and-go concept by a regimen of mFOLFOX7 (inter-
mittent oxaliplatin administration) plus bevacizumab in
Japanese patients with unresectable mCRC. This regimen
was shown to be clinically useful for Japanese patients, with
good tolerability and without impairing treatment efficacy.
Peripheral nerve disorders due to the cumulative toxicity
of oxaliplatin are an obstacle to continuing FOLFOX.
Therefore, a preplanned withdrawal of oxaliplatin for a
period of 8 cycles was set in this study. In order to reduce
hematological toxicity, mFOLFOX7 plus bevacizumab
without 5-FU bolus administration was used, with
bevacizumab co-administered with msLV5FU2 during the
oxaliplatin withdrawal period.
Chemotherapy plus bevacizumab is recommended in the
guidelines of various countries as the first-line therapy for
unresectable mCRC. Comparing the therapeutic effects of
different regimens in phase III studies with PFS as the
primary endpoint, in the NO16966 study, PFS was
9.4 months in the FOLFOX4 plus bevacizumab group and
was 9.3 months in the XELOX plus bevacizumab group
[16], while in the HORIZON III study PFS in the
mFOLFOX6 plus bevacizumab group was 10.3 months
[17]. PFS in this study was 11.8 months, which is compa-
rable to the results of those phase III studies. PFS in the
intermittent administration group of the CONcePT trial [13]
which preceded this study was 12.0 months, a similar result.
Okita et al. [18] conducted mFOLFOX6 (intermittent
oxaliplatin administration) plus bevacizumab by the stop-
and-go concept with Japanese patients as subjects, and the
secondary endpoint PFS was 12.8 months, which is similar
to the results of this study.
Preplanned withdrawal of oxaliplatin is one treatment
strategy against peripheral neuropathy due to cumulative
oxaliplatin toxicity. Peripheral nerve disorders of grade 3
or 4 occurred in 18 % of the FOLFOX4 plus bevacizumab
group in the NO16966 study [19] and in 10 % of the
mFOLFOX6 plus bevacizumab group in the HORIZON
III study [17], but were substantially lower in this study at
3.9 %. Furthermore, peripheral neuropathy of grade 3 or 4
also occurred in 10 % of patients in the intermittent admin-
istration groups in the CONcePT trial [13] and in the study
Table 2 Frequency of common
toxicities (n=51: maximum tox-
icity per patient)
Adverse event All grades n (%) Grade 3 Grade 4 ≥ Grade 3 (%)
Hematological
Leukopenia 14 (27.5) 1 0 (2.0)
Neutropenia 16 (31.4) 3 1 (7.8)
Thrombocytopenia 13 (25.5) 0 0 (0)
Anemia 45 (88.2) 0 1 (2.0)
Non-hematological
Peripheral neuropathy 22 (43.1) 2 0 (3.9)
Allergic reaction 5 (9.8) 1 0 (2.0)
Hypertension 14 (27.5) 2 0 (3.9)
Proteinuria 14 (27.5) 0 – (0)
Hemorrhage 1 (2.0) 0 0 (0)
Venous thromboembolism 2 (3.9) 2 0 (3.9)
Nausea 3 (5.9) 1 0 (2.0)
Vomiting 4 (7.8) 0 0 (0)
Anorexia 3 (5.9) 1 0 (2.0)
Ileus 1 (2.0) 0 1 (2.0)
Diarrhea 1 (2.0) 1 0 (2.0)
Fatigue 1 (2.0) 1 0 (2.0)
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reported by Okita et al. [18]. Therefore, the regimen of this
study was very well tolerated by Japanese patients.
With respect to hematological toxicity, the incidence of
neutropenia of grade 3 or 4 was 40 % in the FOLFOX4 plus
bevacizumab group in the NO16966 study [19] and 24 % in
the mFOLFOX6 plus bevacizumab group in the HORIZON
III study [17], but was lower in this study at 7.8 %. Okita et
al. reported the incidence of neutropenia of grade 3 or 4 to
be 40 % [18], indicating that the mFOLFOX7 without bolus
5-FU regimen that we used in our study is good for keeping
hematological toxicity low.
There are also some interesting study reports related to
continuous oxaliplatin therapy. At the 2012 ASCO Annual
Meeting, Yalcin et al. [20] compared a group that received
continuous XELOX plus bevacizumab until PD with a
group with preplanned withdrawal of oxaliplatin after six
courses (18 weeks) of XELOX plus bevacizumab treatment
and then continued on maintenance therapy of capecitabine
plus bevacizumab. The primary endpoint PFS in the group
that continued with capecitabine plus bevacizumab as main-
tenance therapy was significantly better than PFS in the
group that continued with XELOX plus bevacizumab treat-
ment until PD (capecitabine plus bevacizumab maintenance,
11.0 months [95 % CI, 9.1 to 12.9]; continuous XELOX
plus bevacizumab, 8.3 months [95 % CI, 7.1 to 9.5] [P<
0.002]). This result suggests the possibility that continued
oxaliplatin treatment affects not only tolerability, but also
maintenance of effectiveness.
Although the usefulness of the stop-and-go concept for
unresectable mCRC is becoming established, including the
results of this study, issues still remain from the standpoint
of risk/benefit evaluation.
In representative studies of the stop-and-go concept,
OPTIMOX1 [11] and OPTIMOX2 [12], oxaliplatin was
stopped 12 weeks after the start of treatment, and Yalcin et
al. [20] reported stopping oxaliplatin at 18 weeks after the
start of treatment, while in this study, as in the CONcePT
trial [13], oxaliplatin was stopped at 16 weeks after the start
of treatment, and thus there are differences between studies.
Because the cumulative maximum therapeutic effect
reported by Haller [21] was after about 16 weeks (8 cycles)
of FOLFOX4, and the incidence of peripheral neuropathy of
grade 3 or higher due to oxaliplatin also increased, a
preplanned withdrawal of oxaliplatin after about 16 weeks
with the cumulative dose as guide seems to be most effec-
tive, but this has not yet been established. A clinical study
[22] to resolve this as well as the timing for reintroducing
oxaliplatin is currently underway, and we are awaiting the
results.
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